Mirati Therapeutics Inc.
Clinical trials sponsored by Mirati Therapeutics Inc., explained in plain language.
-
Lung cancer pill study aims to find best dose for shrinking tumors
Disease control OngoingThis study tests two different doses of the targeted drug adagrasib in 200 adults with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. Participants take either 600 mg twice daily without food or 400 mg twice daily with food. The main goal …
Phase: PHASE2 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated May 01, 2026 15:56 UTC
-
New pill targets Hard-to-Treat cancers with KRAS mutation
Disease control OngoingThis study tests an experimental drug called adagrasib (MRTX849) in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if the drug is safe, how the body processes it, and whether it can shrink tumors. About 731 participants …
Phase: PHASE1, PHASE2 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC